SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) will report its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 2:30 p.m. MT to discuss financial results and business progress.
Investors can access a live webcast and replay online. Preregistration is required to join the live call; a PIN code and dial-in number are provided upon registration. A replay will be available starting at 7:30 p.m. ET on the same day.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | earnings date | Neutral | +10.2% | Scheduled first-quarter results and investor call; the 24-hour reaction was 10.18%. |
| Mar 18 | earnings date | Neutral | -3.4% | Scheduled fourth-quarter and year-end results; the 24-hour reaction was -3.4%. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-date notices produced mixed 24-hour reactions of 10.18% and -3.4%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its second quarter financial results after market close on Wednesday, August 12, 2026, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Wednesday, August 12, 2026, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here. |
| Register for the call: | Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration. |
| A replay of the call will be available after 7:30 p.m. ET and can be accessed here. | |
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
